Cardiac Myocardial Injury Associated with Hematopoietic Stem Cell Transplantation in Children
Conditions
Interventions
Blank group:Blank control
Intervention group:Empagliflozin
Sponsors
West China Second University Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
2 Years to 16 Years
Inclusion criteria
Inclusion criteria: 1.Written informed consent was obtained from study participants and/or legal guardians in accordance with regional or Institutional Review Board (IRB) requirements; 2.Children with indications for hematopoietic stem cell transplantation after discussion by the transplantation team of the Department of Hematology at West China Second University Hospital; 3.Study participants were aged >=2 years and <=16 years;
Exclusion criteria
Exclusion criteria: 1. Previous use of other anti-cardiac remodeling agents such as ACEIs, ARBs, beta-blockers, and MRA; 2.History of hypersensitivity to empagliflozin, enalapril, or any component of the medication; 3.Patients with concomitant other cardiac diseases: such as structural heart disease, cardiomyopathy, valvular heart disease, ischemia sexually transmitted diseases; 4.Cases with incomplete clinical data or poor image quality that cannot be analyzed; 5.Participants who have participated in other clinical studies within the past three months; 6.History of impaired liver function/historic portal hypertension/historic liver cirrhosis/pancreatitis; 7.History of chronic renal impairment/eGFR <30; 8.History of type I diabetes mellitus; 9.Parents failed to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overall longitudinal strain of the left ventricle; | — |
Secondary
| Measure | Time frame |
|---|---|
| Myocardial Enzymology; | — |
Countries
China
Contacts
Public ContactGao Ju
West China Second University Hospital, Sichuan University
Outcome results
None listed